Krystal Biotech, Inc.(KRYS) Stock Research - Grey Stern Research

Krystal Biotech, Inc. (KRYS) Stock Analysis

$179.76 (-4.19%)

KRYS Financial Performance


Use the table below to view Krystal Biotech, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $179.76 -
52 Week Low $101.34 -
52 Week High $219.34 -
Market Cap $5.2 Billion 1/6
Gross Margin 90% 2/6
Profit Margin 32% 1/6
EBITDA margin 27% 1/6
Q2 - 2024 Revenue $83.8 Million 2/6
Q2 - 2024 Earnings $27.2 Million 1/6
Q2 - 2024 Free Cash Flow $57.8 Million 1/6
Trailing 4 Quarters Revenue $241.5 Million 2/6
Trailing 4 Quarters Earnings $52.4 Million 1/6
Quarterly Earnings Growth 182% 1/6
Annual Earnings Growth 133% 1/6
Quarterly Revenue Growth 0% 5/6
Annual Revenue Growth 0% 5/6
Cash On Hand $374.0 Million 2/6
Short Term Debt $1.3 Million 5/6
Long Term Debt $0 5/6

Krystal Biotech, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Krystal Biotech, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 98.72 1/6
PS 21.41 3/6
PB 5.84 4/6
PC 13.82 3/6
Liabilities to Equity 0.11 6/6
ROA 0.05 1/6
ROE 0.06 1/6
Current Ratio 10.18 1/6
Quick Ratio 6.10 1/6
Long Term Debt to Equity 0.00 5/6
Debt to Equity 0.00 6/6
Burn Rate -13.92 6/6
Cash to Cap 0.07 4/6
CCR 2.13 1/6
EV to EBITDA 213.85 1/6
EV to Revenue 19.86 3/6

Company Details

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

CEO: Mr. Krish S. Krishnan

Website: https://www.krystalbio.com

Address: 2100 Wharton St Ste 701 Pittsburgh, PENNSYLVANIA

Exchange: NASDAQ Global Market

Industry: Biotechnology

Krystal Biotech, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Krystal Biotech, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
REGENXBIO Inc. RGNX $433.0 Million
Apellis Pharmaceuticals, Inc. APLS $4.2 Billion
Deciphera Pharmaceuticals, Inc. DCPH $2.2 Billion
Rhythm Pharmaceuticals, Inc. RYTM $3.6 Billion
MeiraGTx Holdings plc MGTX $470.5 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
KRYS Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 83.8 Million $27.2 Million
Q1 2024 $ 70.3 Million $15.6 Million
Q4 2023 $ 45.3 Million $932,000
Q3 2023 $ 42.1 Million $8.7 Million
Q2 2023 $ 0 -$33.2 Million
Q1 2023 $ 0 -$41.8 Million
Q4 2022 $ 0 -$29.3 Million
Q3 2022 $ 0 -$29.9 Million

View All

KRYS Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $374.0 Million $982.3 Million $1.3 Million $885.8 Million
Q1 2024 $345.8 Million $917.7 Million $7.7 Million $838.9 Million
Q4 2023 $359.0 Million $853.3 Million $7.9 Million $799.2 Million
Q3 2023 $358.3 Million $818.4 Million $8.1 Million $778.6 Million
Q2 2023 $275.9 Million $684.0 Million $8.5 Million $653.1 Million
Q1 2023 $140.7 Million $531.8 Million $8.8 Million $489.6 Million
Q4 2022 $161.9 Million $558.5 Million $8.9 Million $522.2 Million
Q3 2022 $186.4 Million $576.4 Million $1.5 Million $540.8 Million

View All

KRYS Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 $57.8 Million -$1.0 Million $28.2 Million
Q1 2024 -$5.3 Million -$1.1 Million -$13.2 Million
Q4 2023 $14.6 Million -$1.3 Million $678,000
Q3 2023 -$9.1 Million -$1.8 Million -$14.9 Million
Q2 2023 -$37.0 Million -$2.8 Million $135.1 Million
Q1 2023 -$31.5 Million -$5.4 Million -$21.2 Million
Q4 2022 -$27.5 Million -$5.2 Million -$24.5 Million
Q3 2022 -$33.7 Million -$14.1 Million -$32.3 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions